Bristol-Myers Squibb Co. (BMY) said Tuesday that the U.S. Food and Drug Administration has approved its biologics manufacturing facility in Devens, Massachusetts for commercial production of Orencia (abatacept).
The Devens facility is a bulk biologics manufacturing facility that employs about 300 skilled workers.
"The approval of our Devens site is an important milestone for Bristol-Myers Squibb as part of our strategic focus on delivering innovative biologic medicines for patients with serious disease," said Lou Schmukler, president, Global Manufacturing & Supply, Bristol-Myers Squibb.
"The increased manufacturing capacity from the Devens site will support market demand for ORENCIA and positions us well for future production of additional biologic medicines."
Bristol-Myers Squibb manufactures its biologic medicines in a company-owned facility in Syracuse, NY and through third party suppliers. The company said the Syracuse site will remain a key component of its biologics strategy and will serve as a center of excellence in process development and early product launch for the company's biologic medicines.
For comments and feedback: editorial@rttnews.com